Search for a trial

Wireless Micro Current Stimulation: adjunctive therapy for hard-to-heal chronic wounds * a double-blind, placebo controlled trial

Our aim is to determine whether Wireless Micro Current Stimulation accelerates wound healing in hard-to-heal chronic wounds as compared to standard wound care treatment by conducting a double-blind, placebo controlled trial.

Evaluation of different wound dressings in the treatment of children with spoke injuries

To study wether a biodressing impregnated with polyhexamethylene biguanide in the treatment of spoke injuries in children could give a reduction in pain during the treatment compared to the standard treatment with wound dressing impregnated with

A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis

See above

Does local application of betamethasonvalerate 0.1% cream twice a day reduce the complaints of chronic chilblains?

Research question:Does thin application of betamethasonvaleraat cream 0,1% on perniones lesions twice a day reduce the symptoms of patients as determined in 1st. line health care, with at least 10 mm expressed on a visual analogue scale, together…

Does Nifedipine 60 mg per day per os reduce the complaints of chronic chilblains?

Research question: Does oral administration with regulated release of 60 mg nifedipine a day reduce the symptoms of patients as determined in 1st. line health care, provided there is a good tolerancy of the medication.

A randomized, double-blind, placebo controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate to severe chronic hidradenitis suppurativa patients

1. To determine the efficacy of CJM112 300 mg in chronic hidradenitis suppurativa (HS) patients, by clinical responder rate at week 16.2. To assess the safety and tolerability of CJM112 in patients with chronic hidradenitis suppurativa (HS)3. To…

Phase I , single-center, open-label, two-period study to investigate the pharmacokinetics of the DMF-containing formulation FP187-GC in healthy volunteers after oral administration in fasted and fed state

Primary objective* To investigate the plasma pharmacokinetics of the first metabolite of dimethyl fumarate (DMF) - monomethyl fumarate (MMF) - following administration of the delayed- and slow-release FP187-GC tablet formulation after single dose…

A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with
moderate to severe plaque psoriasis (CAIN457A2317)

Primary: To demonstrate the superiority of secukinumab in subjects with moderate to severe plaque psoriasis based on the proportion of PASI 90 responders at Week 16, compared to ustekinumab.Secondary: To demonstrate the superiority of secukinumab in…

Pit Excision with Phenolisation of the Sinus Tract vs. Radical Excision in Sacrococcygeal Pilonidal Sinus Disease; A Randomised Controlled Trial

The objective of this study is to show that excision of the pit of the sinus of SPSD with phenolisation of the sinus tract is accompanied with sooner return to normal daily activities compared to local excision of the sinus with only a small…

Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 week study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg s.c.

This study will assess if a more prolonged dose interval (every 6 weeks compared to every 4 weeks) will allow psoriasis patients who achieveclear or almost clear skin after 24 weeks of secukinumab treatment - Psoriasis Area and Severity Index (PASI…

A Phase I, single-center, open-label, randomized four-period, randomized five-period or randomized two period crossover study to investigate the pharmacokinetics of five different DMF-containing formulations of FP187 and the comparator products Tecfidera® and Fumaderm® in healthy volunteers after oral administration in fasted or fed state

Part IPrimary objectiveTo investigate the pharmacokinetics of the main metabolite of dimethyl fumarate (DMF) - monomethyl fumarate (MMF) - following administration of 3 different controlled release tablet formulations (FP187: V1, V2B, and V3B) and…

A randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, safety, tolerability and efficacy of omiganan BID in patients with mild to moderate atopic dermatitis

Primary Objective- To assess efficacy and pharmacodynamic effects of topical omiganan BID Secondary Objectives- To assess safety and tolerability of topical omiganan BID

A Randomized, Double-Blind, Multicenter, Equivalence Study of ONS-3010 and Humira® for the Treatment of Patients with Moderate to Severe Plaque Psoriasis

Primary:• To demonstrate the therapeutic equivalence of ONS-3010 (adalimumab biosimilar) compared toHumira® (adalimumab) in patients with plaque psoriasis Secondary:• To assess the safety, tolerability, and immunogenicity of ONS-3010 compared to…

Fingertip Injury and Treatment; an internal audit.

The objective of this retrospective study is to compare the outcome of the different treatment options(surgical or non-surgical) for fingertip injury.

A randomized, double-blind, placebo-controlled, parallel group study evaluating efficacy and safety of QAW039 in the treatment of patients with moderate to severe atopic dermatitis (CQAW039X2201)

Primary objective: To evaluate the efficacy of once daily doses of QAW039, as measured by EASI after 12 weeks of treatment, relative to placebo, in adult patients with moderate to severe AD. To evaluate safety and tolerability.Secondary objectives:…

The effect of Staphefekt on the skin microbiome, including Staphylococcus aureus, in patients with atopic dermatitis.

To retrieve (in vivo) data about the effect of Staphefekt on the microbiome, including Staphylococcus aureus, and on disease severity in patients with atopic dermatitis.

A first-in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome (CBPR277X2101)

Primary: (part 3) Potential of BPR277 1% ointment b.i.d. to improve the clinical severity of lesional skin in the majority of NS patients at end of treatment versus baseline of >= 2 points, dose range and regimen relationship on clinical…

A randomized, double-blind, placebo controlled, parallel group, proof of concept study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with moderate to severe atopic dermatitis (CQGE031X2201)

Primary: To demonstrate the efficacy of QGE031 relative to placebo at 12 weeks in patients withatopic dermatitis (AD) as assessed by Eczema Area and Severity Index (EASI).Secondary: efficacy assessed by Investigator Global Assessment (IGA, 12 weeks…

Measuring the dynamic characteristics of skin tension of the human body

Research question: What is the influence of anatomical position changes on the skin tension and direction of highest tension in healthy participants at different locations of the body?

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo

Primary:To evaluate the efficacy of ruxolitinib cream in participants with vitiligo.Secondary:To further assess the efficacy of ruxolitinib cream.To evaluate the safety and tolerability of ruxolitinib cream.To evaluate the ruxolitinib PK in plasma…